Dopaminergic Drugs in Congestive Heart Failure: Hemodynamic and Neuroendocrine Responses to Ibopamine, Dopamine, and Dihydroergotoxine

@article{Metra1995DopaminergicDI,
  title={Dopaminergic Drugs in Congestive Heart Failure: Hemodynamic and Neuroendocrine Responses to Ibopamine, Dopamine, and Dihydroergotoxine},
  author={Marco Metra and Cristina Missale and PierFranco Spano and Livio dei Cas},
  journal={Journal of Cardiovascular Pharmacology},
  year={1995},
  volume={25},
  pages={732–740}
}
Ibopamine has hemodynamic and neurohumoral effects potentially useful for the treatment of congestive heart failure (CHF), but its mechanism of action is not completely clear. To evaluate the role of dopaminergic receptor stimulation in the hemodynamic and neurohumoral activity of ibopamine, we compared the effects of ibopamine, 100 mg orally (p.o.) with those of dopamine 2, 4, and 6 μg/kg/min intravenously (i.v.) and of the DA2 agonist dihydroergotoxine 6 μg/kg i.v. in 13 patients with chronic… 
Clinical efficacy of ibopamine in patients with chronic heart failure
Ibopamine, the most widely studied dopaminergic drug for the treatment of chronic heart failure, appears to have beneficial hemodynamic, renal, and neurohormonal effects in this setting.
Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection FractionCLINICAL PERSPECTIVE
TLDR
In this post hoc analysis of ROSE AHF, the response to vasoactive therapies differed in patients with heart failure with reduced EF and heart failure With preserved EF, Investigations of AHF therapies should assess the potential for differential responses in AHF with preserved versus reduced EF.
Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).
TLDR
In this post hoc analysis of ROSE AHF, the response to vasoactive therapies differed in patients withHeart failure with reduced EF and heart failure with preserved EF, and Investigations of AHF therapies should assess the potential for differential responses in AHF with preserved versus reduced EF.
Terapia con inotropi nello scompenso cardiaco acuto: rivisitazione critica delle evidenze scientifiche e cliniche per levosimendan nel contesto del trattamento tradizionale
TLDR
Criteria for the appropriate use of inotropic agents in acute heart failure is suggested, based on a critical appraisal of the existing evidence and clinical experience, according to an expert consensus.
Can drug effects on mortality in heart failure be predicted by any surrogate measure?
TLDR
None of the parameters discussed above is perfect when used alone, but the most promising surrogates are heart rate variability, QT dispersion and plasma neurohormones, the first two for sudden death and the last one for death from progressive disease.
Predicting the Animal Susceptibility and Therapeutic Drugs to SARS-CoV-2 Based on Spike Glycoprotein Combined With ACE2
TLDR
Assessment of the receptor utilization capacity of ACE2s from 10 kinds of animals shows that chimpanzees, domestic cats and cattles are more susceptible to infection by SARS-CoV-2, suggesting the necessity to carefully evaluate the risk of cats during the current COVID-19 pandemic.
Intravenous positive inotropic therapy for acute decompensated heart failure
TLDR
Avrupa ülkelerinde 75 yafl’n alt›ndaki hastalarda kalp yetersizli¤inin en s›k nedeni koroner arter hastal›¤›na ba¤l› miyokard disfonksiyonudur.
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.
TLDR
It is of great importance that guidelines and recommendations are presented in formats that are easily interpreted and their implementation programmes must also be well conducted.
Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Versión resumida
Rev Esp Cardiol. 2005;58(4):389-429 389 ÍNDICE DE CONTENIDOS Preámbulo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 390 1. Introducción . . . . . . . . . . . . . . . . . . . . . . .
...
...